OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0195

Erythropoiesis Stimulating Agents (ESAs)

Customize your policy alerts

Sign up for Aetna Policy 0195 alerts

Get alerted when Policy 0195 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage, dosing, coding, and indications for erythropoiesis stimulating agents (epoetin alfa, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, peginesatide, and related products) as applied to Aetna members.

Policy Summary

PayerAetna

PolicyErythropoiesis Stimulating Agents (ESAs)

Policy CodePolicy 0195

Change TypeNo material change

Effective DateJan 6, 1998

Last ReviewJan 9, 2024

Next Review DateNov 14, 2024

Key ActionObtain prior authorization with documentation of indication, hemoglobin, and iron status before ESA initiation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~160references cited

96trials in Cochrane review

manyexperimental indications

10–12 g/dLHb thresholds cited

safety/paymentFDA/CMS actions

Coverage Criteria and Indications

FDA-approved indications / Coverage criteria

Covered when ALL of the following FDA/compendial criteria are met (by indication):

CKD (adults): Anemia due to chronic kidney disease (CKD): epoetin alfa or methoxy polyethylene glycol-epoetin beta (Mircera) when used to decrease the need for red blood cell (RBC) transfusion in patients on dialysis or not on dialysis; Mircera starting dose 0.6 mcg/kg IV or SC once every 2 weeks for adults not currently treated with an ESA; IV route recommended for hemodialysis patients.

Refer to product labeling for dosing adjustments and route-specific recommendations; IV route may be less immunogenic for hemodialysis patients.

Chemotherapy-induced anemia (non-myeloid malignancy): Anemia due to myelosuppressive chemotherapy in non-myeloid malignancies: initiate ESA only if hemoglobin is less than 10 g/dL and there is a minimum of two additional months of planned chemotherapy; use the lowest ESA dose necessary to avoid RBC transfusion; discontinue following completion of the chemotherapy course.Hb < 10 g/dL; >=2 months planned chemotherapy

Starting doses include darbepoetin alfa 2.25 mcg/kg weekly or 500 mcg every 3 weeks; follow FDA labeling for dose adjustments; ESAs are not indicated when anticipated outcome is cure.

Policy Summary

PayerAetna

PolicyErythropoiesis Stimulating Agents (ESAs)

Policy CodePolicy 0195

Change TypeNo material change

Effective DateJan 6, 1998

Last ReviewJan 9, 2024

Next Review DateNov 14, 2024

Key ActionObtain prior authorization with documentation of indication, hemoglobin, and iron status before ESA initiation.

SourceLink

On This Page

HIV-related anemia: Anemia due to zidovudine therapy in patients with HIV infection: epoetin alfa indicated when endogenous serum erythropoietin is ≤ 500 mUnits/mL and zidovudine dose is ≤ 4,200 mg/week.endogenous EPO <= 500 mUnits/mL; zidovudine <= 4200 mg/week

Follow product labeling for dosing and monitoring.

Perioperative (select elective, noncardiac, nonvascular surgeries): Epoetin alfa indicated to reduce need for allogeneic RBC transfusions in patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk of perioperative blood loss for elective, noncardiac, nonvascular surgery.Hb >10 to <=13 g/dL

Not indicated for patients willing to donate autologous blood preoperatively; concurrent DVT prophylaxis recommended due to increased thrombotic risk.

Compendial Uses / NCCN

Compendial / guideline-supported coverage (NCCN) for chemotherapy-induced anemia in palliative patients:

NCCN alternative regimens: For persons undergoing palliative chemotherapy, NCCN lists alternative dosing regimens for darbepoetin alfa and epoetin alfa (fixed-dose darbepoetin weekly/biweekly/triweekly with specified uptitration; epoetin alfa 80,000 units q2w or 120,000 units q3w).

Use per NCCN guidance and product labeling; apply same initiation criteria (Hb <10 g/dL and ongoing chemotherapy) and risk–benefit discussion.

Experimental and Investigational (Not covered)

Not covered / Experimental and investigational for the following indications:

Experimental/Investigational indications: Use of ESAs is considered experimental and investigational for indications not supported by peer-reviewed literature; examples include acute renal injury, anemia associated only with radiotherapy, COPD-associated anemia, anemia due to bleeding (except specified high‑risk surgical settings), anemia due to nutritional deficiencies or hemolysis, anemia of prematurity, aplastic anemia, prophylactic use to prevent chemotherapy‑induced anemia or tumor hypoxia, sickle cell anemia, sepsis‑associated anemia, traumatic brain injury, out‑of‑hospital cardiac arrest, nephron‑protection in kidney transplant, and other conditions listed in policy.

Extensive list provided in policy; these indications are generally not eligible for coverage absent strong, peer‑reviewed evidence or trial participation.

FDA-indicated uses (initial therapy)

Covered when ALL of the following are met

FDA indication and treatment intent: Patient has an FDA‑approved indication (CKD‑related anemia, anemia due to myelosuppressive chemotherapy in non‑myeloid malignancy with ≥2 additional months planned, anemia due to zidovudine in HIV with low endogenous EPO, or perioperative reduction of RBC transfusion in select elective noncardiac nonvascular surgery) and treatment intent aligns with labeling (not to promote cure or prophylaxis).

Discontinue following completion of chemotherapy; avoid ESA use when anticipated outcome is cure.

Baseline laboratory and iron assessment: Documentation of baseline hemoglobin and iron status including transferrin saturation and ferritin, with iron deficiency addressed prior to ESA initiation (transferrin saturation ≥20% and ferritin ≥100 ng/mL recommended).TSAT >=20%; ferritin >=100 ng/mL

Ferritin may be falsely normal with inflammation; assess iron appropriately.

Risk assessment and monitoring plan: Documentation of blood pressure control, absence of prior ESA‑related pure red cell aplasia (PRCA) or neutralizing antibodies, and a plan for hemoglobin monitoring and dose adjustment to use the lowest ESA dose sufficient to avoid transfusion without exceeding recommended hemoglobin thresholds.

Reduce or withhold dose as hemoglobin approaches 11–12 g/dL per labeling; discontinue in non‑responders per product guidance.

Contraindications and restricted uses

Not recommended / restricted

Prophylactic or cure‑directed use: Use of ESAs to prevent chemotherapy‑induced anemia prophylactically or use during myelosuppressive chemotherapy when the anticipated outcome is cure is not recommended per FDA labeling and compendial guidance.

Labeling explicitly advises against prophylactic use to prevent chemotherapy‑induced anemia or to reduce tumor hypoxia.

Prior PRCA or neutralizing antibodies: Patients with a history of pure red cell aplasia (PRCA) associated with ESA therapy or suspected anti‑erythropoietin neutralizing antibodies should not receive ESAs.

Withhold ESA if antibody‑associated anemia suspected.

Uncontrolled hypertension is a contraindication; blood pressure should be adequately controlled prior to initiation and monitored during therapy.

Hypertensive encephalopathy and seizures have been observed; control BP before and during ESA therapy.

Chemotherapy-induced anemia

Use considered under condition-specific contexts with risk-benefit discussion

Chemotherapy-induced anemia: For patients receiving myelosuppressive chemotherapy with hemoglobin less than 10 g/dL, clinicians should discuss potential harms (thromboembolism, shorter survival) and benefits (reduced transfusions); if ESA therapy is chosen, use the lowest effective dose to avoid transfusion and monitor response, discontinuing after 6–8 weeks in non‑responders.Hgb < 10 g/dL

Shared decision‑making is required; follow FDA labeling for initiation and dose modification.

Chronic heart failure

Heart failure patients with anemia — evidence summary and research need

Heart failure anemia: Small randomized trials and meta‑analyses suggest ESAs can improve exercise tolerance, 6‑minute walk distance, and some cardiac parameters in anemic patients with chronic heart failure, but larger trials are needed to confirm clinical benefit and define safety; clinicians should weigh potential symptomatic benefit against risks (thrombosis, cerebrovascular events).

Evidence heterogeneous; awaiting results from larger trials (eg, RED‑HF).

Acute MI / STEMI

Acute myocardial infarction / STEMI

ESA in STEMI/acute MI: Trials (including REVEAL) showed no reduction in infarct size and reported higher rates of adverse cardiovascular events in some subgroups (older patients); systematic reviews give mixed results and caution is advised when considering ESA use in acute MI or periprocedural PCI contexts.

Single‑dose IV epoetin within 4 hours of PCI did not reduce infarct size and was associated with higher adverse events in subgroup analyses; routine use not supported.

AKI prevention (biomarker-triggered)

AKI prevention in ICU using biomarker-triggered ESA

Biomarker-triggered early EPO: Randomized biomarker‑triggered trial used urinary biomarker concentration product > 46.3 to enroll critically ill patients; early high‑dose EPO was safe but did not change primary AKI outcomes and transient biomarker elevations limited triage effectiveness.biomarker product > 46.3

Not effective for improving AKI outcomes in cited study; investigational approach.

Breast cancer adjuvant chemotherapy

Adjuvant breast cancer chemotherapy

Use in breast cancer chemotherapy: Epoetin alfa reduced transfusion requirements and prevented hemoglobin decline in adjuvant breast cancer trials but increased thrombotic events (eg, 7% vs 3%); no impact on relapse‑free or overall survival was observed in some trials — risks must be weighed particularly in curative settings.

Evidence does not support improved survival; consider non‑ESA alternatives and risk discussion.

Rheumatoid arthritis

Rheumatoid arthritis-associated anemia

ESA in rheumatoid arthritis: Randomized trials of EPO in rheumatoid arthritis are small, heterogeneous, and at high or unclear risk of bias with inconsistent effects on quality of life and hemoglobin; safety profile unclear — further independent studies needed.

Evidence insufficient to support routine ESA use for RA‑associated anemia outside selected contexts.

Preterm infants / retinopathy of prematurity

Neonatal retinopathy / preterm infants

EPO in preterm infants: Preclinical and some clinical data suggest possible neuroprotective effects of EPO in preterm infants, but retrospective studies have associated EPO with severe oxygen‑induced retinopathy; timing, dosing, and safety windows are uncertain and clinical use remains investigational for neuroprotection and retinopathy prevention.

Further trials required to define benefit and safety; current use typically within research protocols.

Traumatic brain injury

Traumatic brain injury (TBI)

EPO in severe TBI trial: Randomized trials comparing EPO versus placebo and different transfusion thresholds showed no improvement in favorable neurological outcomes at 6 months; no interaction observed and results do not support routine ESA use for neurological recovery after TBI.enrollment within 6 hours of injury (trial cited)

Use in TBI considered not effective based on available RCT data.

Cancer-related anemia (ESA consideration)

Coverage considerations reflect benefits (reduced transfusions) versus safety risks (thromboembolism, hypertension, possible mortality signal).

Cancer-related anemia coverage logic: ESA therapy for cancer‑related anemia is covered when the patient has symptomatic anemia due to chemotherapy, hemoglobin below conventional thresholds after evaluation and correction of iron or other causes, iron status has been assessed/managed as appropriate, and the prescriber documents discussion of ESA risks (thromboembolism, hypertension, potential mortality signal) and plans for monitoring and dose adjustment.

Balance transfusion‑sparing benefits against thrombotic and possible survival risks; use lowest effective dose and discontinue in non‑responders.

Preoperative use in craniosynostosis

Preoperative pediatric craniosynostosis — ESA used as a blood conservation strategy.

Preoperative pediatric craniosynostosis coverage logic: Covered when ALL of the following are met: planned craniosynostosis repair with expected significant blood loss; documented preoperative ESA dosing protocol and iron supplementation per studied regimens; concurrent blood conservation measures (eg, cell saver) and acceptance of lower transfusion triggers included in the perioperative plan; baseline and expected benefit documented.

Evidence from small RCTs and cohort studies demonstrates reduced transfusion rates; document protocol and monitoring.

Other/experimental or limited indications

Other indications: mixed evidence or investigational/limited use.

Other indications with limited or conflicting evidence: ESAs have mixed or preliminary evidence in indications such as STEMI/PCI, traumatic brain injury, COPD‑related anemia, heart failure, adjunctive use in beta thalassemia, and cognitive/neurologic conditions; coverage for these indications generally requires strong justification, protocolized care, or enrollment in clinical trials.

Some trials show harm or no benefit (eg, OHCA, TBI); others are small/pilot and require confirmatory data.

ESA use in lower-risk MDS (initial trial and continuation)

Covered when ALL of the following are met per cited guideline:

MDS ESA trial criteria: 1) Patient has IPSS low or intermediate‑1 (INT‑1) myelodysplastic syndrome (MDS); 2) Patient has symptomatic anemia; 3) Patient meets criteria for a high or intermediate predictive score for ESA response; 4) For non‑sideroblastic phenotypes offer ESA alone; for sideroblastic phenotypes offer ESA plus G‑CSF; 5) Trial limited to a maximum of 16 weeks (8 weeks at starting dose ± G‑CSF then up to 8 weeks at higher dose if needed); 6) Continue only if complete or partial erythroid response is achieved, using the minimum effective ESA dose to maintain response.maximum trial period 16 weeks

Based on British Committee for Standards in Haematology guidelines (Killick et al, 2014); continue long‑term only if response maintained.

Beta thalassemia — HU plus EPO evidence

Evidence (single RCT) shows possible benefit when ALL of the following are present:

Beta thalassemia HU+EPO study findings: In transfusion‑dependent beta thalassemia intermedia (≤18 years) receiving hydroxyurea, addition of recombinant human EPO (1,000 IU/kg/week divided) produced greater increases in hemoglobin and HbF and a higher rate of conversion to transfusion independence versus HU alone; larger trials and longer follow‑up are needed to define responders and long‑term safety.

Proof‑of‑principle RCT in 80 subjects; not yet standard of care.

HIE — investigational adjunct to hypothermia

Evidence is preliminary; ESA use in HIE is investigational and may be used in the context of clinical trials or pilot protocols when ALL apply:

HIE ESA use considerations: Small pilot and early‑phase trials combining erythropoietin with therapeutic hypothermia (and sometimes magnesium sulfate) show feasibility and preliminary safety, but studies are small, often uncontrolled, and not powered for efficacy; use is investigational and should be restricted to clinical trials or research protocols until phase III results are available.

Phase III trials (eg, HEAL) are ongoing; practice outside trials not routinely recommended.

Kidney transplant — nephron-protection

Not covered as nephron-protective standard therapy because trials show no consistent benefit:

KTx nephron-protection evidence: Peri‑operative high‑dose rHuEPO did not reduce delayed graft function (DGF) in kidney transplant recipients in RCTs and meta‑analyses; some analyses found higher systolic blood pressure in treated patients — not supported as standard nephron‑protective therapy.

Not covered for nephron protection absent new supportive evidence.

Neonatal hemolytic disease — supportive use

Use may be considered in select neonatal hemolytic anemia with inadequate reticulocyte response when ALL of the following are present:

Neonatal hemolytic anemia ESA use: Selected neonates with hemolytic disease and hyporegenerative anemia (inadequate reticulocyte response) may receive EPO to stimulate erythropoiesis and potentially avoid transfusion; evidence primarily from small cohorts and case series and randomized confirmation is lacking.

Document reticulocyte production index and failure of expected regenerative response; consider EPO within specialty protocols.

Hereditary hemochromatosis — EPO + erythrocytapheresis

Consider in patients intolerant of phlebotomy when ALL apply:

HH combined therapy: In hereditary hemochromatosis patients intolerant of phlebotomy, low‑dose EPO administered between erythrocytapheresis sessions can prevent anemia and facilitate ferritin reduction; evidence from retrospective series supports feasibility but prospective comparative data are lacking.

Consider only when phlebotomy is not tolerated and under specialist supervision.

MDS — Trial of ESA

Guideline-supported ESA use in myelodysplastic syndromes:

MDS — Trial of ESA: Lower‑risk MDS patients (IPSS low or INT‑1) with symptomatic anemia who meet predictive score criteria should be offered an ESA trial (with or without G‑CSF for sideroblastic phenotypes) for up to 16 weeks; continue only if erythroid response achieved and maintain at minimum effective dose.maximum trial period 16 weeks

Recommendations per BCSH guidelines; document IPSS risk, predictive score, and response assessments.

Myelofibrosis — Considerations and caution

Evidence and expert consensus on ESA use in myelofibrosis:

Myelofibrosis ESA considerations: ESA may be considered to treat anemia in primary myelofibrosis primarily for patients who are not transfusion‑dependent, with lower baseline hemoglobin and possibly low serum EPO; response rates are modest (eg, ~23–37%) and ESA use requires caution given limited data and potential risks.

Avoid in transfusion‑dependent patients or those with Hb ≥10 g/dL; consider baseline serum EPO when available.

Preoperative rHuEPO + iron — Coverage criteria

Preoperative anemia management with rHuEPO + iron:

Preoperative ESA + iron criteria: Adult patients with preoperative anemia undergoing non‑cardiac surgery may be eligible for preoperative rHuEPO plus iron when the intent is to reduce perioperative RBC transfusion and concurrent iron supplementation is provided; high‑dose rHuEPO (500–600 IU/kg) increased preoperative Hb and reduced transfusion need in trials.

Consider cost‑effectiveness and balance risks/benefits; document anemia diagnosis, dosing intent, iron therapy, and transfusion‑sparing goals.

Investigational / research indications

Investigational or in-research indications with ongoing trials:

Neonatal encephalopathy / neuroprotection: EPO shows neuroprotective effects in animal models and early‑phase clinical trials; large phase III trials (eg, HEAL) are ongoing — use confined to clinical trials or research protocols until definitive evidence is available.

Clinical use outside trials not routinely recommended.

Optic neuritis: Phase II data suggest EPO may preserve retinal nerve fiber layer thickness in acute optic neuritis; confirmatory phase II/III trials (eg, TONE) are ongoing and EPO use remains investigational pending definitive results.

Trial dosing examples provided in literature; use only in trial settings.

Preterm/low birth‑weight infants: Clinical studies report potential neurodevelopmental benefit of ESAs in preterm infants but evidence remains evolving; consideration generally limited to neonatal trial settings or specialty protocols.

Long‑term neurodevelopmental outcomes are under investigation; routine use not established.

OHCA — contraindicated by evidence

Indications with evidence of no benefit and increased harm:

OHCA — not beneficial: Out‑of‑hospital cardiac arrest (OHCA): early high‑dose EPO did not improve neurological outcomes or mortality and was associated with higher rates of serious adverse events, particularly thrombotic complications (eg, serious AEs 22.6% vs 14.9%).trial dosing example: up to 200,000 total units given as 5 IV injections of 40,000 units spaced 12 hours

Use in OHCA is contraindicated by trial evidence and associated safety signal.

The policy explicitly excludes numerous diagnoses and scenarios from coverage. Examples of experimental or investigational and excluded indications include: anemia of prematurity; anemia associated only with radiotherapy; anemia related to chronic obstructive pulmonary disease; anemia due to bleeding (except specified high‑risk surgical indications); anemia due to folate, B12, or iron deficiency, hemolysis, or bone marrow fibrosis; aplastic anemia; many infectious and inflammatory conditions; hereditary hemochromatosis; hypoxic‑ischemic encephalopathy and other neonatal encephalopathies; immediate correction of severe anemia (i.e., substitution for RBC transfusion); prophylactic use to prevent anticancer chemotherapy‑induced anemia or tumor hypoxia; sickle cell anemia; sepsis‑associated anemia; traumatic brain injury; out‑of‑hospital cardiac arrest; and other neurologic, cardiac, congenital, and systemic conditions listed in the policy.

Providers should reference the full exclusion list when submitting requests because the policy enumerates many ICD‑10–level conditions (for example, codes for retinopathy of prematurity, neonatal encephalopathy, cardiac arrest, hemolytic anemias, aplastic anemia, sarcoidosis, and others) that are not covered when the indication falls within these excluded scenarios.

Mircera (methoxy polyethylene glycol‑epoetin beta) is approved and indicated for correction and maintenance of anemia due to chronic kidney disease, including patients on and not on dialysis; however, Mircera is not indicated for treatment of anemia due to cancer chemotherapy and is not recommended as a substitute for immediate correction of anemia by red blood cell transfusion in patients who require urgent hemoglobin restoration.

Mircera carries the same class boxed safety warnings as other ESAs (increased risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression/recurrence) and is contraindicated in patients with uncontrolled hypertension or known hypersensitivity to the product; these labeling limits further support restricting Mircera from oncology chemotherapy indications and from use as an immediate transfusion alternative.

Authorized Regimens and Trial Protocols

Indication / Context	Regimen (dosing examples)	Notes / Limits
Chemotherapy-induced anemia (non-myeloid malignancy)	Darbepoetin alfa: 2.25 mcg/kg subcutaneously weekly; or 500 mcg subcutaneously every 3 weeks	Initiate only if hemoglobin < 10 g/dL and there is a minimum of two additional months of planned chemotherapy; use lowest ESA dose necessary to avoid RBC transfusion; discontinue following completion of chemotherapy (Amgen, 2019).
Chemotherapy-induced anemia — NCCN alternative fixed‑dose darbepoetin regimens	Darbepoetin alfa fixed doses: 100 mcg SC weekly (may increase to 150–200 mcg weekly); 200 mcg SC every 2 weeks (may increase to 300 mcg q2w); 300 mcg SC every 3 weeks (may increase to 500 mcg q3w)	NCCN lists these as alternative regimens for persons undergoing palliative treatment; follow product labeling for uptitration.
Chemotherapy-induced anemia — epoetin alfa fixed‑dose options (NCCN)	Epoetin alfa: 80,000 units SC every 2 weeks; or 120,000 units SC every 3 weeks	NCCN alternative regimens; apply FDA initiation criteria (Hb < 10 g/dL and ≥2 months planned chemotherapy) and use lowest effective dose.

Indication	Trial schedule	Treatment decision rule
Lower‑risk myelodysplastic syndromes (IPSS low or INT-1) — symptomatic anemia	Maximum trial period 16 weeks composed of: 8 weeks at the starting dose of ESA ± G‑CSF, then up to 8 additional weeks at higher doses if required	Continue long‑term only if complete or partial erythroid response achieved; maintain at the minimum ESA dose required to sustain response (BCSH Killick et al., 2014).

Indication / Phenotype	Recommended approach	Duration / Continuation
Lower‑risk MDS with sideroblastic phenotype	Trial of ESA (darbepoetin or epoetin) plus or minus G‑CSF (offer ESA + G‑CSF for sideroblastic phenotypes)	Maximum trial period up to 16 weeks (8 weeks starting dose ± G‑CSF, then up to 8 weeks at higher dose if needed); continue only if erythroid response obtained, using minimal effective dose (Killick et al., 2014).

Indication	Applicability	Guidance
Anemia in cancer patients receiving myelosuppressive chemotherapy	Use epoetin alfa, darbepoetin alfa, or other FDA‑labeled ESAs for this indication as listed in FDA‑approved brands	Use per FDA‑approved labeling; initiation criteria include hemoglobin < 10 g/dL and planned additional chemotherapy (see product prescribing information).

Billing Codes, Hemoglobin Thresholds, and Lab Criteria

HCPCS/J-codes (covered if selection criteria met / listed)HCPCS

J0885	Injection, epoetin alfa, (for non-ESRD use), 1,000 units
J0887	Injection, epoetin beta, 1 microgram, (for ESRD on dialysis)
J0888	Injection, epoetin beta, 1 microgram, (for non-ESRD use)
Q4081	Injection, epoetin alfa, 100 units (for ESRD on dialysis)
Q5105	Injection, epoetin alfa, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units
Q5106	Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units
S9537	Home therapy; hematopoietic hormone injection therapy; administrative services, per diem
J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)
J0890	Injection, peginesatide, 0.1 mg (for ESRD on dialysis)

1–10 of 11

1/2

CPT Codes related to CPBCPT

38204-38232	Bone Marrow or Stem Cell Services/Procedures
38240-38243	Transplantation and Post-Transplantation Cellular Infusions
96372, 96374-96376	Therapeutic, prophylactic, or diagnostic injection
96401-96417	Chemotherapy administration
99601-99602	Home infusion/specialty drug administration

ICD-10 codes (covered if selection criteria met / examples)ICD-10

B20	Human immunodeficiency virus [HIV] disease
D64.81	Anemia due to antineoplastic chemotherapy
N18.1-N18.9	Chronic kidney disease (CKD)
D63.0-D63.8	Anemia in chronic diseases classified elsewhere
D50.0-D50.9	Iron deficiency anemia
P07.00-P07.03	Extremely low birth weight newborn

ICD-10 codes (not covered examples)ICD-10Not Covered

A49.01-A49.9	Bacterial infection (listed as not covered when selection criteria met)
D55.0-D59.9	Hemolytic anemias [hereditary and acquired] (not covered)
D62	Acute posthemorrhagic anemia (not covered)
G35	Multiple sclerosis (not covered)
O99.011-O99.03	Anemia complicating pregnancy, childbirth and the puerperium (not covered)

Covered/affected codesmixed

affected codes

placeholder — coding for ESA administration and products referenced in this document portion

inv-51: Hemoglobin threshold for chemotherapy-induced ESA initiation

Chemotherapy-induced anemia initiation thresholdHemoglobin < 10 g/dL required to initiate ESA for anemia due to myelosuppressive chemotherapy (and at least two additional months of planned chemotherapy).

Documentation requirementAt initiation document hemoglobin value and plan for ≥2 additional months of myelosuppressive chemotherapy.

Dose intentUse the lowest ESA dose necessary to avoid RBC transfusions per product labeling (e.g., darbepoetin 2.25 mcg/kg weekly or 500 mcg q3w).

inv-52: Hemoglobin thresholds

General initiation guidanceInitiation generally when hemoglobin < 10 g/dL (clinical context/guidelines recommend discussion of harms/benefits at Hgb <10 g/dL).

Avoid targeting high HbDo not exceed or target hemoglobin > 11–12 g/dL; reduce dose if Hgb approaches 12 g/dL (Procrit labeling) and adjust per FDA guidance to avoid >11–12 g/dL in CKD patients.

Dose adjustment triggersReduce or interrupt dose if hemoglobin increases by >1 g/dL within any 2-week period; withhold if Hgb exceeds 12 g/dL until it falls below 11 g/dL (labeling).

Non-responder discontinuationDiscontinue ESAs in non-responders after 6–8 weeks per guideline recommendations if no adequate Hb response.

inv-53: Iron indices

Transferrin saturation minimumTransferrin saturation (iron saturation) should be ≥ 20% prior to ESA initiation.

Ferritin minimumSerum ferritin should be ≥ 100 ng/mL prior to ESA initiation (note ferritin may be falsely normal in inflammation).

Iron assessment requirementEvaluate iron stores (TSAT and ferritin) and ensure adequate folate/B12 prior to starting ESA therapy.

inv-54: ESRD hematocrit/hemoglobin threshold

ESRD monitoring threshold (hematocrit)Hematocrit > 39.0% is the CMS threshold that prompts dose reduction/payment adjustment interventions.

ESRD monitoring threshold (hemoglobin)Hemoglobin > 13.0 g/dL for 3 or more consecutive billing cycles triggers CMS dosing/payment reductions for dialysis patients.

CMS actionFor hematocrit above threshold, reported ESA dose for which payment may be made may be reduced (historical CMS policy reflected).

inv-55: AKI biomarker concentration product

AKI biomarker triggerRandomization in the cited AKI trial was triggered by a urinary biomarker concentration product > 46.3.

Clinical implicationBiomarker product > 46.3 identified higher-risk patients but was transient and did not lead to improved outcomes with early high-dose EPO in the trial.

inv-56: Hemoglobin consideration

Guideline hemoglobin considerationGuidelines discuss hemoglobin < 10 g/dL in the chemotherapy context as the usual trigger for discussion/consideration of ESA therapy (not an absolute initiation target for all contexts).

Shared decision-makingFor patients with Hgb <10 g/dL undergoing myelosuppressive chemotherapy, clinicians should discuss risks (thromboembolism, shorter survival) and benefits (reduced transfusion).

Lowest effective doseIf used, administer the lowest ESA dose to increase Hb only to the minimum needed to avoid transfusion and reassess in 6–8 weeks for response.

inv-57: Serum erythropoietin level

Serum EPO and response in myelofibrosisBaseline serum erythropoietin < 125 U/L has been associated with better ESA response in myelofibrosis, but this is not uniformly predictive.

Response heterogeneityESA response in myelofibrosis varies (reported response rates ~23–37%) and is not reliably predicted solely by serum EPO level.

Clinical use cautionAvoid ESA in transfusion-dependent myelofibrosis or in patients with baseline hemoglobin ≥ 10 g/dL; consider serum EPO when assessing likelihood of response.

inv-58: Epoetin alfa weekly exposure to darbepoetin conversion

Conversion overviewManufacturer-supplied conversion table maps weekly epoetin alfa exposure (IU/week) to weekly darbepoetin doses (mcg/week) across ranges (e.g., <1500 → 6.25 mcg/week; 1500–2499 → 6.25 mcg/week; 2500–4999 → 12.5 mcg/week; up to ≥90,000 → 200 mcg/week).

Pediatric notesSome pediatric cells in the conversion table note insufficient data for certain low-dose categories; follow manufacturer guidance for pediatric conversions.

Source guidanceUse the manufacturer's conversion table when switching from epoetin alfa IV/SQ to darbepoetin dosing to document prior exposure and new dosing.

inv-59: Reference ranges

Serum iron normal rangesSerum iron: Children 50–120 mcg/dL; Men 80–180 mcg/dL; Newborns 100–250 mcg/dL; Women 60–160 mcg/dL.

Serum ferritin normal rangesSerum ferritin: Female 12–150 ng/mL; Male 12–300 ng/mL.

Use in documentationInclude pertinent reference ranges for iron and ferritin in clinical documentation when assessing iron status prior to ESA initiation.

Prior Authorization, Documentation, and Safety Actions

Prior Authorization

Prior authorization for HCPCS/J-codes

Authorization is required for administration of ESAs and related HCPCS/J-codes; specific HCPCS/J-codes are payable only if selection/coverage criteria are met.

Covered HCPCS/J-codes include J0885, J0887, J0888, Q4081, Q5105, Q5106, S9537, J0881, J0882, J0890, J2916 when selection/coverage criteria are documented.

Prior Authorization

Prior authorization for ESA therapy

Prior authorization must confirm the FDA‑indicated diagnosis (e.g., CKD-related anemia, zidovudine-treated HIV with low endogenous EPO, or chemotherapy‑induced anemia with at least two additional months of planned myelosuppressive chemotherapy) and document that therapy will use the lowest dose sufficient to avoid transfusion per labeling.

Chemotherapy-induced anemia: hemoglobin < 10 g/dL and ≥2 months planned chemotherapy required for initiation.
CKD and perioperative indications must be consistent with FDA labeling and product-specific dosing.

Documentation Required

Hemoglobin/hematocrit monitoring requirement

Documentation of serial hemoglobin/hematocrit is required; regulatory/payer guidance requires dose reduction or interruption when Hb/Hct exceed specified thresholds in ESRD patients receiving dialysis.

CMS monitoring: hematocrit >39.0% or hemoglobin >13.0 g/dL for 3+ consecutive billing cycles triggers dose/payment adjustments.
Follow FDA guidance to reduce or withhold ESA dose if hemoglobin approaches or exceeds 11 g/dL (non-dialysis) or exceeds 11 g/dL (dialysis patients per labeling guidance).

Prior Authorization

Prior authorization for ESA use

Prior authorization must ensure ESA prescribing aligns with FDA labeling (use only for indicated diagnoses, dosing per product label, and avoidance of ESA use when cure is the anticipated outcome).

Do not initiate ESAs for patients receiving myelosuppressive chemotherapy if the anticipated outcome is cure.
Use the lowest dose necessary to avoid RBC transfusion and discontinue in non-responders after 6–8 weeks.

Prior Authorization

Prior authorization requirements for ESAs

Prior authorization requests must include documentation of the indication, current hemoglobin, iron evaluation and correction, and prior therapies before approving ESA therapy.

Required: baseline hemoglobin, transferrin saturation and ferritin, folate/B12 status, transfusion history, and chemotherapy plan (if applicable).
For cancer-related use, document risk/benefit discussion including thromboembolism and hypertension risks.

Prior Authorization

Prior authorization considerations for ESA trials

Prior authorization for ESA trials should reflect recommended trial periods and monitoring (e.g., guideline-supported MDS trial up to 16 weeks) and consider thrombosis risk and dose‑holding rules.

MDS: trial structure—8 weeks at starting dose ± G-CSF, then up to 8 weeks at higher dose; continue only if erythroid response achieved.
Utilization review may require documentation of planned trial duration and response assessments.

Prior Authorization

Preoperative rHuEPO + iron — authorization considerations

Authorization for preoperative rHuEPO plus iron should require documentation of the anemia diagnosis, planned dosing intent (high vs low dose), and concurrent iron therapy, since combined rHuEPO + iron reduced perioperative transfusion in trials.

Document that concurrent iron supplementation will be provided and the clinical goal is reduction of RBC transfusion.
Consider cost‑effectiveness and reserve routine preoperative ESA use for select high‑risk cases with documented rationale.

Prior Authorization

Prior authorization: FDA‑approved indications

Prior authorization must be supported by FDA‑approved indications and brand labeling (CKD, zidovudine‑treated HIV with low EPO, chemotherapy‑induced anemia with ≥2 additional months planned chemotherapy, or perioperative reduction of transfusion in specified surgical patients).

Mircera, Aranesp, Epogen/Procrit/Retacrit listed in FDA-approved indications appendix.
Off‑label uses require strong justification and supporting evidence.

Note

No PA rules in this section

This reference section lists prescribing information and guideline citations but does not itself establish additional prior authorization rules; follow the policy's authorization module for requirements.

Note

Prior authorization and policy review

Follow Aetna policy and prior authorization procedures as posted; policy is maintained and reviewed by Aetna and should guide coverage determinations.

Policy last reviewed 01/09/2024; next review 11/14/2024.

Billing Rule

Product conversion/step guidance

Document prior ESA dosing and dosing rationale when converting between products (use provided conversion tables for epoetin alfa → darbepoetin and Mircera conversion guidance).

Include previous epoetin alfa weekly dose when calculating darbepoetin or Mircera starting dose per Appendix C and product labeling.
Provide rationale for frequency change (eg, switching to less frequent Mircera dosing when Hb stabilized).

Billing Rule

Step/conversion guidance

When requesting conversion or longer‑interval products (eg, Mircera) for CKD-related anemia, document that hemoglobin was stable on prior ESA and provide the conversion calculation per manufacturer guidance.

Mircera is not indicated for chemotherapy‑induced anemia; conversions apply primarily in CKD contexts.
Provide evidence of stable Hb (±1 g/dL) before conversion consideration.

Note

Trial-preferred use for cancer-related anemia

For chemotherapy‑induced anemia, NICE advised ESA use only within clinical trials due to uncertain survival and thromboembolism effects; document when trial participation is applicable.

NICE assessment noted modest transfusion reductions but uncertain effects on survival; consider trial enrollment where relevant.

Step Therapy

Step to transfusion/conservative care

Prior authorization reviewers should consider RBC transfusion and conservative management as alternatives and require documentation that less‑risk options (iron therapy, transfusion) were considered prior to ESA initiation.

Document trials of iron therapy (IV or oral) and any recent transfusion history.
ESAs should be used at the lowest effective dose to minimize attained hemoglobin and thrombotic risk.

Step Therapy

Step therapy: trial of iron or transfusion-first strategies

For cancer patients, document that iron status was assessed and corrected as appropriate and that transfusion‑first or iron‑first strategies were considered before initiating ESAs.

Provide transferrin saturation, ferritin, and any iron therapy given.
Rationale for ESA vs iron/transfusion should be explicit in the prior authorization record.

Step Therapy

Stepwise ESA trial in MDS

For MDS, prior authorization should reflect guideline‑recommended stepwise ESA trial: initial 8 weeks at starting dose (± G‑CSF) then up to 8 additional weeks at higher dose for non‑responders before deeming failure.

Document IPSS risk (low or INT‑1), symptomatic anemia, predictive response score, trial start date, and planned response assessments.
Continue ESA only if complete/partial erythroid response achieved; use minimum effective dose.

Note

Step therapy and cost-effectiveness note

Routine preoperative ESA use for elective surgery is not considered cost‑effective; prior authorization should reserve ESAs for select high‑risk cases after iron trial and documented rationale.

Require documentation of why IV iron or other PBM measures are insufficient and the expected benefit of ESA therapy.

Documentation Required

Perioperative management preference

Perioperative anemia management prioritizes IV iron and treatment of underlying causes; ESAs are not standard perioperative management and require justification if requested.

Document iron indices and rationale for ESA if IV iron alone is inadequate.
Provide planned blood conservation measures (eg, cell saver) when preoperative ESA use is proposed.

Note

No step therapy requirements are specifi

No specific step therapy mandates are listed in the references; however, guideline citations (KDIGO, NCCN, ASCO/ASH) in the policy inform preferred sequencing and authorization decisions.

Use referenced guideline recommendations to inform sequencing when evaluating prior authorization requests.

Note

Guideline-informed sequencing

Guideline and compendium references (NCCN, ASCO/ASH, SEOM) should be used to inform preferred sequencing and alternatives to ESAs when evaluating authorization requests.

NCCN Hematopoietic Growth Factors guidance and compendia entries (Aranesp, epoetin alfa) are referenced for oncology use.

Documentation Required

Documentation for chemotherapy-induced anemia

For chemotherapy‑induced anemia prior authorization, include documentation of hemoglobin (< 10 g/dL) and evidence of at least two additional months of planned myelosuppressive chemotherapy.

Document chemotherapy regimen, planned duration (≥2 months), and hemoglobin value at initiation.
Confirm discussion of risks/benefits and plan for monitoring Hb response.

Documentation Required

Documentation for conversions and dosing

When converting products, prior authorization must include dosing rationale and record of prior ESA dosing used for conversion calculations (eg, epoetin alfa weekly dose to darbepoetin or Mircera conversion).

Append conversion table entries or manufacturer guidance to support dose calculations.
Include date and dose of most recent ESA administrations.

Documentation Required

Required baseline and monitoring data

Required documentation for prior authorization must include baseline and on‑therapy hemoglobin, iron studies (transferrin saturation and ferritin), folate and B12 status, concomitant chemotherapy plan when applicable, and prior PRCA/neutralizing antibody history.

Transferrin saturation ≥ 20% and ferritin ≥ 100 ng/mL are expected before initiation when feasible.
Include transfusion history and planned monitoring schedule.

Billing Rule

ESA dosing/payment monitoring for ESRD

For ESRD patients on dialysis, prior authorization/claims require hematocrit/hemoglobin monitoring records because CMS applies payment and dosing adjustments for hematocrit >39% (or Hb >13.0 g/dL) over multiple billing cycles.

Provide serial Hct/Hb values across billing cycles to support dosing and payment adjudication.
Be prepared for CMS‑based dose reduction/payment limitations if thresholds exceeded for 3+ consecutive cycles.

Documentation Required

Document Hgb, indication, and response

Document hemoglobin values, indication, shared decision‑making discussion of risks/benefits, dosing per FDA label, and an evaluation of response within 6–8 weeks to justify continuation or discontinuation.

For non‑responders after 6–8 weeks, document decision to discontinue ESA.
Record any dose adjustments and Hb trends (eg, increases >1 g/dL in 2 weeks).

Documentation Required

Required clinical documentation for cancer-related use

For cancer‑related ESA use prior authorization, include hemoglobin levels, iron assessment and correction, chemotherapy schedule and intent (curative vs palliative), transfusion history, and explicit rationale given ESA risks.

Hemoglobin threshold for initiation generally <10 g/dL; ensure at least two additional months of planned myelosuppressive chemotherapy.
Document discussion of thromboembolic and hypertension risks and plan for monitoring.

Documentation Required

Preoperative pediatric documentation

For preoperative pediatric craniosynostosis ESA use, prior authorization must include the indication, detailed preoperative EPO dosing schedule, iron supplementation plan, planned surgery date, transfusion alternatives and blood‑conservation measures.

Provide baseline and anticipated preoperative Hb/Hct and the protocol for intra‑operative cell salvage and transfusion triggers.

Documentation Required

MDS documentation for ESA trial

For MDS ESA trials, prior authorization should include IPSS risk (low or INT‑1), symptomatic anemia documentation, predictive score for ESA response, planned trial duration and response assessment schedule.

Document phenotype (sideroblastic vs non‑sideroblastic) and whether G‑CSF will be combined with ESA if indicated.
Limit trial to maximum 16 weeks per guideline (8+8 week strategy).

Documentation Required

Required clinical documentation for ESA consideration

For ESA consideration in MDS/myelofibrosis, include IPSS risk category, predictive response score, phenotype, transfusion dependence status, baseline hemoglobin and serum erythropoietin level when available.

For myelofibrosis avoid ESA in transfusion‑dependent patients or those with baseline Hb ≥ 10 g/dL unless compelling rationale documented.
Include prior transfusion frequency and response expectations.

Documentation Required

Required supporting lab and dosing conversion information

Include laboratory reference ranges (serum iron, ferritin) and the epoetin‑to‑darbepoetin conversion table in the documentation when relevant to dosing/conversion requests.

Append Appendix B reference ranges and Appendix C conversion table when submitting conversion requests.

Documentation Required

Supporting literature

Attach bibliographic references, clinical trials, guideline citations, and product prescribing information to support medical necessity determinations when requesting authorization for less common or investigational ESA uses.

Relevant sources include Cochrane NMA, NCCN, ASCO/ASH guidelines, and manufacturer prescribing information.

Documentation Required

Product prescribing information

Include product prescribing information (manufacturer PI) for the specific ESA product requested (eg, Epogen/Procrit/Retacrit, Aranesp, Mircera) as supporting documentation for product‑specific dosing and labeled indications.

Manufacturer PI provides dose‑holding rules (eg, withhold if Hb exceeds labeled thresholds) and boxed warnings to inform authorization decisions.

Denial Risk

Denial risk for experimental/investigational indications

Submission of ESAs for experimental or investigational indications listed in the policy may be denied; ensure requests are for FDA‑approved or guideline‑supported indications with supporting evidence.

Examples of experimental/non‑covered uses include anemia of prematurity, prophylactic prevention of chemotherapy‑induced anemia, sepsis‑associated anemia, sickle cell anemia, and out‑of‑hospital cardiac arrest.

Denial Risk

Risk when Hb targets exceeded

Use of ESAs to achieve or maintain hemoglobin targets above recommended levels (eg, exceeding ~11–12 g/dL or initiating therapy contrary to labeling) is associated with increased mortality and cardiovascular risk and may trigger denial or requirement for justification.

FDA and trial data show higher risks when targeting Hb >11 g/dL; use the lowest dose to avoid transfusion and follow dose‑hold rules for Hb rises >1 g/dL in 2 weeks.

Denial Risk

Conditions triggering noncoverage per CMS

CMS has determined ESAs are not reasonable and necessary for multiple conditions (eg, anemia due to cancer treatment with uncontrolled hypertension; anemia associated only with radiotherapy; anemia due to nutritional deficiencies, hemolysis, bleeding, bone marrow fibrosis; prophylactic use to prevent chemotherapy‑induced anemia), which may lead to noncoverage determinations.

Prior authorization should exclude ESA use for CMS‑listed noncovered conditions unless compelling evidence and case review justify exception.

Denial Risk

Clinical caution and labeling adherence

Authorization reviewers will apply clinical caution and require adherence to FDA labeling — avoid ESA use in cancer patients not receiving concurrent chemotherapy (except select low‑risk MDS) and discontinue if non‑responsive after 6–8 weeks.

Ensure blood pressure is controlled prior to initiation and monitored during therapy; withhold for uncontrolled hypertension or prior antibody‑mediated PRCA.

Denial Risk

Safety-related denial risk

Safety signals (increased thromboembolic events, hypertension, and possible increased mortality) may prompt denial or require explicit justification and monitoring plans when ESAs are requested.

Cancer trials report ↑ VTE risk (~1.55‑fold) and potential mortality signals; include mitigation and monitoring strategies in authorization requests.

Denial Risk

Ineffective indication denial risk

Use of ESAs for indications demonstrated ineffective (eg, traumatic brain injury) is at high risk of denial; provide robust supporting evidence if seeking coverage for such indications.

TBI trials did not show neurological benefit and may increase adverse events; these uses are considered not medically necessary in policy.

Denial Risk

Thrombosis risk / dosing caution

Exercise caution due to thrombosis risk; prior authorization may require documentation that the lowest ESA dose will be used to avoid transfusion and that ESA will be held if hemoglobin rises rapidly or exceeds label thresholds.

NCCN/CMS/FDA guidance: hold ESA when Hb ≥10 g/dL in some COVID guidance examples and reduce dose if Hb approaches 11–12 g/dL per product labeling.
Document VTE prophylaxis plan in perioperative contexts where ESA used.

Denial Risk

OHCA safety signal

Out‑of‑hospital cardiac arrest (OHCA) indication carries a safety signal: trials showed no benefit and higher serious adverse events (notably thrombotic complications); requests for this indication are expected to be denied.

Phase III OHCA trial: serious AEs 22.6% with EPO vs 14.9% control; thrombotic complications 12.4% vs 5.8%.

Prior Authorization

Alignment with FDA-approved indications

Prior authorization must align ESA use with FDA‑approved indications and recognized brands; off‑label uses described in the background (eg, neuroprotection, TBI) require strong supporting rationale.

Append FDA‑approved indication table (Appendix A) and product PI to support requested use.

Note

This section contains only references

This references section contains only citations and does not itself establish authorization or denial triggers; use the substantive policy sections and prior authorization module for determinations.

Denial Risk

Safety advisory-related denial risk

FDA safety communications and advisories (labeling changes, boxed warnings, dosing modifications) represent safety‑related coverage risks; documentation must show adherence to current FDA dosing and monitoring guidance.

FDA modified dosing recommendations (2011) advising initiation when Hb <10 g/dL and dose reduction/ interruption when Hb approaches/exceeds 11 g/dL.
Include evidence of boxed‑warning counseling and monitoring plans in authorization requests.

Definitions and Key Terms

inv-104: ESA — Erythropoiesis stimulating agent definition and examples

DefinitionErythropoiesis-stimulating agents (ESAs) are biologic therapies (e.g., epoetin alfa, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta) that stimulate red blood cell production.

ExamplesCommon ESA products referenced: epoetin alfa (Epogen, Procrit, Retacrit), darbepoetin alfa (Aranesp), methoxy PEG-epoetin beta (Mircera).

Therapeutic intentUsed to correct anemia, reduce RBC transfusion need, and improve quality of life in approved indications (CKD, zidovudine-treated HIV, certain chemotherapy-associated anemia, select perioperative uses).

inv-105: Chemotherapy-induced anemia initiation criteria

Initiation criteria (chemo-induced anemia)Initiate ESA only if hemoglobin < 10 g/dL and there is a minimum of two additional months of planned myelosuppressive chemotherapy; use the lowest dose necessary to avoid RBC transfusion.

Treatment intent limitationESAs are not indicated for persons receiving myelosuppressive chemotherapy when the anticipated outcome is cure; discontinue following completion of chemotherapy.

Dose examplesDosing examples include darbepoetin 2.25 mcg/kg weekly or 500 mcg every 3 weeks; refer to full prescribing information for adjustments.

inv-106: ESA — alternate short definition entry (epoetin alfa, darbepoetin alfa, etc.)

Short definitionESA — biologic drugs (e.g., epoetin alfa, darbepoetin alfa, methoxy PEG-epoetin beta) that stimulate erythropoietin receptors to increase RBC production.

Common agentsExamples include epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta (Mircera).

Key cautionAgents carry boxed warnings for increased risk of death, MI, stroke, VTE, thrombosis of vascular access, and tumor progression/recurrence in certain settings.

inv-107: Pure red cell aplasia (PRCA)

Definition of PRCAPure red cell aplasia (PRCA) is severe anemia associated with neutralizing antibodies to erythropoietin; prior ESA-related PRCA is a contraindication to further ESA use.

Action if suspectedIf anti-erythropoietin antibody-associated anemia is suspected, withhold Mircera and other ESAs per product labeling.

Safety notePRCA has been associated with development of neutralizing antibodies in patients treated with ESAs in post-marketing experience.

inv-108: Aplastic anemia

Aplastic anemia definitionAplastic anemia is a bone marrow failure syndrome with markedly elevated endogenous erythropoietin levels where ESAs have not been proven effective and may risk antibody-mediated PRCA.

Clinical rationaleRCTs do not show improved outcomes with addition of erythropoietin to immunosuppressive therapy for aplastic anemia.

Guideline stanceBritish Society of Haematology guidelines state routine use of erythropoietin for aplastic anemia is not recommended.

inv-109: ESRD monitoring threshold

CMS hematocrit/Hb thresholdsCMS references hematocrit > 39.0% or hemoglobin > 13.0 g/dL as thresholds prompting dose reduction/payment adjustments for ESRD patients on dialysis.

Payment adjustment detailIf hematocrit/hemoglobin exceed the threshold for 3+ consecutive billing cycles, the erythropoietin analog dose for which payment may be made may be reduced (historical policy).

Clinical monitoringRegulatory guidance emphasizes monitoring and dose modification to avoid high attained hematocrit/hemoglobin in ESRD patients.

inv-110: ESA non-responder

ESA non-responder definitionAn ESA non-responder is a patient who does not have an adequate hemoglobin response after 6–8 weeks of therapy, at which point ESAs should be discontinued per guideline updates and labeling.

Dose adjustment windowLabeling suggests increasing dose if inadequate rise after 4–8 weeks depending on schedule; discontinue if no response by 6–8 (or 16 weeks in some CKD contexts) as appropriate.

Monitoring planAssess hemoglobin response within the specified timeframe and document intent to discontinue if non-response occurs.

inv-111: Thromboembolic events

DefinitionThromboembolic events include venous or arterial thrombosis; meta-analyses and NMA data show ESA use (alone or with iron) slightly increases thromboembolic event rates.

Magnitude of riskNetwork meta-analysis estimated increased thromboembolic events with ESA alone (RR ~1.82) and ESA+IV iron; clinicians should weigh this when considering therapy.

DocumentationDocument discussion of thrombotic risk when initiating ESA therapy, especially in cancer and high-risk patients.

inv-112: Preoperative EPO regimen (example)

Example regimen (preoperative pediatric)Example preoperative EPO regimen in infants/children: 600 U/kg weekly for 3 weeks with supplemental iron used in craniosynostosis studies to raise pre-op Hb and reduce transfusions.

Supportive measuresTrials paired EPO with supplemental iron and strict transfusion criteria and blood-conservation planning.

Evidence baseSmall randomized pediatric trials showed increased pre-op Hb and reduced transfusion rates without noted adverse effects in the cited study.

inv-113: ESA trial (MDS)

MDS ESA trial definitionA therapeutic trial in lower-risk MDS typically consists of up to 16 weeks: 8 weeks at starting ESA dose ± G-CSF, then up to 8 additional weeks at higher dose if needed; continue only if erythroid response achieved.

EligibilityApplied to patients with IPSS low or INT-1 MDS with symptomatic anemia and predictive score for response.

Long-term continuationPatients achieving response should continue on minimal effective ESA dose to maintain response until lost.

inv-114: Lower-risk MDS (IPSS low / INT-1)

Lower-risk MDS definitionLower-risk MDS includes IPSS low and intermediate-1 (INT-1) patients who have symptomatic anemia and may be candidates for ESA therapy per guidelines.

Guideline sourceRecommendations derived from British Committee for Standards in Haematology (Killick et al, 2014).

Trial durationMaximum ESA trial period recommended is 16 weeks with staged dose escalation and response assessment.

inv-115: High-dose vs low-dose rHuEPO (preoperative)

High-dose vs low-dose rHuEPO (preop) definitionsCochrane review defined low dose rHuEPO as 150–300 IU/kg and high dose as 500–600 IU/kg for preoperative use.

Clinical effectHigh-dose rHuEPO + iron associated with increased preoperative Hb and reduced transfusion need in noncardiac surgery trials (moderate-quality evidence).

ConsiderationsWeigh potential benefits against thrombotic risk and cost-effectiveness; use with concurrent iron supplementation per trials.

inv-116: Delayed hemolytic transfusion reaction (DHTR)

DHTR definitionDelayed hemolytic transfusion reaction is a significant drop in hemoglobin within 21 days post-transfusion associated with new alloantibody, hemoglobinuria, HbS% changes, reticulocyte changes, LDH rise, and exclusion of other causes.

Management noteSupportive care may include erythropoietin with or without IV iron as part of management in certain severe hemolytic transfusion reactions.

inv-117: NCCN Drugs & Biologics Compendium

Role of NCCN CompendiumThe NCCN Drugs & Biologics Compendium is cited as a compendium source supporting oncology-related ESA guidance (e.g., Aranesp, epoetin alfa).

Use in policyCompendium entries inform regimen options and clinical guidance for chemotherapy-induced anemia and other oncology contexts.

Line-of-Therapy Groupings

inv-118: any

Any: See coding tables and prior authorization modules for HCPCS/J‑codes, CPT codes, and ICD‑10 examples that apply when selection/coverage criteria are met.

Authorization required for administration of ESAs and related HCPCS codes; specific codes payable only if coverage criteria are satisfied.

inv-119: any

Any: Chemotherapy‑induced anemia initiation criteria: initiate ESA only if hemoglobin < 10 g/dL and there is at least two additional months of planned myelosuppressive chemotherapy; use lowest dose to avoid RBC transfusion.Hb < 10 g/dL; >=2 months planned chemotherapy

Discontinue after completion of chemotherapy; document hemoglobin and chemotherapy plan.

inv-120: mixed

mixed: Evidence from randomized trials in various cancer settings indicates potential harm when targeting higher hemoglobin levels (eg, Hb 12–14 g/dL), including shortened survival in metastatic breast cancer and worse loco‑regional control in head & neck cancer; therefore ESA use in oncology requires adherence to lower thresholds and careful monitoring.

Follow labeling to avoid higher Hb targets; shared decision‑making required.

inv-121: any

Any: Clinical guidance emphasizes discussing harms and benefits with patients receiving myelosuppressive chemotherapy and restricting ESA use to those meeting hemoglobin and chemotherapy duration criteria; avoid ESA use in patients not receiving concurrent chemotherapy (except selected low‑risk MDS).Hgb < 10 g/dL considered contextually

Use lowest effective dose and discontinue in non‑responders after recommended trial period.

inv-122: first-line

first-line: Adjuvant/chemotherapy context: ESAs may be considered for chemotherapy‑induced anemia when initiation criteria are met, but evidence of harm in curative settings mandates restriction and careful risk–benefit discussion; follow FDA and guideline labeling for dosing and monitoring.

Avoid routine ESA use when anticipated outcome is cure; consider alternatives such as transfusion and iron therapy.

inv-123: first-line

first-line: MDS first‑line: lower‑risk MDS patients with symptomatic anemia should undergo an ESA trial (maximum 16 weeks) prior to other cytotoxic therapies; continue only if erythroid response achieved.16-week trial period recommended

Document IPSS risk, predictive score, and response assessments.

Dose Conversion Tables and Reference Ranges

inv-127: Use of ESAs per FDA‑approved labeling

Labeling adherenceUse ESAs per FDA‑approved labeling and regimen examples listed in product prescribing information (CKD, zidovudine-treated HIV, chemotherapy-induced anemia, perioperative transfusion reduction).

Product examplesBrands include Epogen, Procrit, Retacrit, Aranesp, Mircera as listed in the FDA-approved indications appendix.

Regulatory contextPolicy references product prescribing information and regulatory guidance when confirming medical necessity for ESA use.

inv-58: Epoetin alfa weekly exposure (IU/week) to darbepoetin conversion

Conversion mapping (excerpt)Epoetin alfa weekly exposure categories map to darbepoetin weekly mcg doses: <1500 → 6.25 mcg; 1500–2499 → 6.25 mcg; 2500–4999 → 12.5 mcg; 5000–10,999 → 25 mcg; 11,000–17,999 → 40 mcg; 18,000–33,999 → 60 mcg; 34,000–89,999 → 100 mcg; ≥90,000 → 200 mcg (adult values per manufacturer table).

SourceManufacturer conversion table (Amgen, 2019) provided in Appendix C for switching epoetin alfa to darbepoetin dosing.

inv-59: Reference ranges

Serum iron reference rangesSerum iron normal ranges: Children 50–120 mcg/dL; Men 80–180 mcg/dL; Newborns 100–250 mcg/dL; Women 60–160 mcg/dL.

Serum ferritin reference rangesSerum ferritin normal ranges: Female 12–150 ng/mL; Male 12–300 ng/mL.

Use caseInclude these laboratory reference ranges in clinical documentation when assessing iron status prior to ESA initiation or conversion decisions.

Background and Evidence Summary

Erythropoiesis‑stimulating agents (ESAs) such as epoetin alfa, darbepoetin alfa and methoxy polyethylene glycol‑epoetin beta stimulate red blood cell production by activating the erythropoietin receptor on erythroid progenitors, increasing proliferation and maturation of red cell precursors. These agents are used to correct anemia, reduce the need for allogeneic blood transfusions, and in some settings to improve quality of life.

This policy addresses the permitted and not‑permitted uses of ESAs across clinical contexts, aligning coverage with FDA‑approved indications (for example, anemia due to chronic kidney disease, zidovudine‑treated HIV with low endogenous EPO, reduction of transfusions in selected perioperative patients, and chemotherapy‑induced anemia when specific criteria are met), compendial guidance, and evidence‑based restrictions driven by safety concerns (including boxed warnings for increased risk of death, cardiovascular events, thromboembolism, and tumor progression).

Operationally, coverage determinations require documentation of the specific FDA‑indicated diagnosis, baseline hemoglobin and iron indices, and a monitoring plan to use the lowest ESA dose sufficient to avoid transfusion while avoiding hemoglobin targets associated with increased harm.

Randomized controlled trial evidence demonstrates that use of erythropoietin after out‑of‑hospital cardiac arrest (OHCA) provides no clinical benefit and increases harm. A phase III multicenter RCT administering high‑dose EPO (five IV injections of 40,000 units over 48 hours; maximum 200,000 units) found no improvement in neurological outcome or mortality and reported a higher rate of serious adverse events in the EPO group (22.6% vs 14.9%), notably thrombotic complications (12.4% vs 5.8%; p = 0.01).

Based on these randomized data and the broader safety profile of ESAs (thrombosis, cardiovascular events), the policy excludes use of EPO for OHCA and flags this indication as contraindicated by evidence of no benefit and increased serious adverse events.

Policy Dates and Revision History

1998-01-06policy_effective

Policy originally became effective.

2024-01-09policy_reviewLatest

Policy most recently reviewed and maintained by Aetna.

2024-11-14policy_next_review

Scheduled next policy review date.